Molecular Neurobiology and Neurochemistry of Addiction, National Institute of Psychiatry, Ramón de la Fuente Muñiz, Mexico.
Molecular Neurobiology and Neurochemistry of Addiction, National Institute of Psychiatry, Ramón de la Fuente Muñiz, Mexico.
Eur J Pharmacol. 2018 Feb 5;820:183-190. doi: 10.1016/j.ejphar.2017.12.033. Epub 2017 Dec 19.
Exposure to cues previously associated with drug use and the environment can trigger intense craving and drug-seeking, often leading to relapse in individuals with substance use disorders. Several studies suggest that the decrease in the effects of the cues and the environment could help maintain abstinence from drug use in individuals abusing drugs. Mirtazapine, an antagonist of the noradrenergic (NE) α receptor and the 5-HT and 5-HT receptors has demonstrated efficacy in reducing the rewarding effect of different drugs. The purpose of the present study was to investigate whether the mirtazapine, blocks the acquisition and reinstatement of cocaine-induced conditioned place preference (CPP). In this study, 120 Wistar male rats were utilized and we use the CPP as a behavioral tool to measure the context-rewarding effect of an unconditioned stimulus such as cocaine. Mirtazapine was dosed for 30 or 60 consecutive days prior to treatment with cocaine or during the extinction phase. We found that dosing with mirtazapine for 30 consecutive days caused a time-related reduction in acquisition or reinstatement of preference for the cocaine-paired chamber. When the duration of treatment is increased (60 days), reductions in preference for the cocaine-paired chamber were potentiated. These observations support its potential clinical anti-addictive properties against drugs.
暴露于先前与药物使用和环境相关的线索会引发强烈的渴望和觅药行为，这通常导致患有物质使用障碍的个体复发。几项研究表明，减少线索和环境的影响可以帮助维持滥用药物的个体戒除药物使用。米氮平是去甲肾上腺素（NE）α受体和 5-HT 和 5-HT 受体的拮抗剂，已证明其在减少不同药物的奖赏效应方面具有疗效。本研究的目的是研究米氮平是否阻断可卡因诱导的条件位置偏好（CPP）的获得和复燃。在这项研究中，使用了 120 只雄性 Wistar 大鼠，我们使用 CPP 作为一种行为工具来测量未条件刺激（如可卡因）的环境奖赏效应。米氮平在可卡因治疗前或消退阶段连续 30 或 60 天给药。我们发现，连续 30 天给予米氮平会导致对可卡因配对室的获得或复燃偏好的时间相关减少。当治疗持续时间延长（60 天）时，对可卡因配对室的偏好减少得到增强。这些观察结果支持其对药物具有潜在的临床抗成瘾特性。
